SCL was commissioned to be a reliable supplier and CDMO services provider for Pharmaceutical intermediates and APIs
SCL was incorporated on 20th December 1993 as a Private Limited Company. It initially began its operations by manufacturing Intermediates. Later, on 1st July 1997, the Company was reconstituted as a Public Limited Company and subsequently was renamed to its present name. In 2004, SCL set up a new facility for API manufacturing and currently offers a wide range of APIs and Advanced Intermediates to its Customers. These APIs and Advanced Intermediates cater to diverse Therapeutic segments such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Cardiology, Anti-cholinergic, Central Nervous System (CNS), Anti-filarials, Anthelmintics, etc.

SCL has over the years expanded its presence across the globe with key export markets being Europe (France, Spain, Germany, Italy, Greece, Austria, Portugal, Slovenia, Netherlands, Denmark), the United States of America (USA), Turkey, Japan, Korea, Brazil, Russia & CIS countries, South & Central America, Middle East & Northern Africa (MENA) region & other Asian countries.
The Company is headquartered at Panchkula (Haryana) near Chandigarh and has 2 Manufacturing facilities (one each for intermediates & APIs) located at Derabassi, Mohali (Punjab). Marketing office for the company is based out of Delhi NCR. Company has acquired 22acres of land for adding facilities near the existing site.
The Manufacturing facilities of the Company comply with the United States Food and Drug Administration (USFDA), European Union Good Manufacturing Practices (EU-GMP), TGA Australia, MFDS Korea & Japanese Pharmaceutical and Medical Devices Agency (JPMDA).
SCL is an API Manufacturing Company
established in Early 90’s
2002
Becomes largest supplier of Cephalosporin & Penem Intermediates in India2005-2008
First EU GMP Certification of API site in 2005, Subsequent approvals by Danish and German Authorities in, 2008, 2011, 2012 & 20152014
SCL receives WHO Geneva GMP approval2016
USFDA Approval Received in March’16. WHO GENEVA EmpanelmentKFDA Approval received. First CEP received2018
Third USFDA audit, EIR received, Third WHO GMP audit1990's
First manufacturing facility (for Intermediates) set up in late 90’s2004
API manufacturing site set up2013
Joint Venture with Mitsubishi Corporation, Japan2015
AFM registration with PMDA, Japan EU GMP by Danish Medicine, TGA Empanelment2017
Second USFDA audit conducted (Zero 483s), Second KFDA approval Purchase of New Greenfield Site
Our Values
Respectful Of Compliance
True Partners To Our Customers
Commmitment To Quality
Transparent Working
Create Cost Effective Solutions
Focus On Results
Know more about SCL Mission & Vision
Know more about SCL Vision & Mission
- Delivering Value to life to Health
- Efficacy and Purity of products to enhance quality of human life
Complete compliance to the international standards of Health & Environment
- Committed to cause of Planet & People
Harnessing India’s knowledge skills for alleviating human suffering.
To be an Internationally recognized supplier of APIs and Pharmaceutical Intermediates to the regulated Markets.
To offer CMO Services for the regulated markets.
- Delivering Value to life to Health
- Efficacy and Purity of products to enhance quality of human life
- Complete compliance to the international standards of Health & Environment
- Committed to cause of Planet & People
- Harnessing India’s knowledge skills for alleviating human suffering.
- To be an Internationally recognized supplier of APIs and Pharmaceutical Intermediates to the regulated Markets.
- To offer CMO Services for the regulated markets.